DxS

DxS is a diagnostics company with a focus on personalized medicine and companion diagnostics. Having developed a highly sensitive diagnostic, able to determine a patient's suitability for cancer treatments according to their genetic status, DxS works with pharma companies to develop companion diagnostics for their oncology drugs. To date, DxS' Therascreen tests have been developed for mutations in K-Ras and EGFR genes.

College Hill has worked with DxS to highlight the advantages offered by its diagnostics through a communications programme which has involved the extensive use of newsflow to raise awareness of DxS, coupled with a media briefing programme, conference support, and the identification of high profile feature opportunities.

• To raise awareness of DxS as the partner of choice for pharma companies seeking a companion diagnostic
• To communicate the growing use of companion diagnostics in oncology
• To position DxS as a leader in the field of personalised medicine

Our Approach

• Extensive use of newsflow such as deals with pharma companies, new products and appointments were used to ensure DxS was kept in the news
• A briefing programme with key media to ensure they understood DxS, and the benefits of its diagnostic tests
• Media support around conferences, including arranging media briefings
• Identification of feature opportunities to position DxS as leaders in the field of companion diagnostics

DxS is now well known to the media, with over 350 pieces of coverage secured over an 18 month period, including repeated mentions in top tier media such as BioCentury, Clinica, Dow Jones, Dow Jones Venture Wire, GEN, Scrip, Genomeweb and Pharmacogenomics. The profile of the company has helped it achieve recognition and awareness in the industry, reflected by the fact that DxS' was acquired by QIAGEN for £95m in September 2009.

Joanne Cross, Marketing Manager at DxS commented: "College Hill's work has ensured DxS is now known as one of the leading companies in the companion diagnostics field and, through the constant coverage, DxS has rarely been out of the news."

November 2009

To discuss our capability in this area please contact:
Sue Charles, Managing Partner
+44 (0)207 457 2020
sue.charles[at]collegehill.com

© 2010 College Hill Associates | Registered in England No 1036926 / VAT No 245666930 | Legal

other clients